Skip to main content

Table 4 Data on mean (SD) primary outcome measures at 3 and 6-months follow-up in the intervention group (n = 71) and control group (n = 75) and the estimated effect of the multidisciplinary lifestyle intervention on cardiovascular risk factors compared with the control group

From: The effect of a comprehensive lifestyle intervention on cardiovascular risk factors in pharmacologically treated patients with stable cardiovascular disease compared to usual care: a randomised controlled trial

Primary outcome measure Baseline   Baseline to 3 months   6-months  
  Intervention, n = 71 mean (SD) Control, n = 75 mean (SD) Intergroup differencesaB(95% CI) p Intergroup differencesaB(95% CI) p
Weight, kg 86.0 (15.0) 88.0 (20.6) −1.3 (−2.2/-0.4)** b 0.004 −1.3 (−2.5/-0.1)**b 0.03
Body mass index, kg/m 2 28.7 (4.4) 29.8 (5.4) −0.5 (−0.8/-0.2)** b 0.002 −0.5 (−0.9/-0.1)**b 0.02
Waist circumference, cm 101.2 (13.4) 101.0 (14.7) −2.5 (−4.0/-1.0)** 0.001 −0.2 (−2.0/1.6)** 0.82
Systolic BP, mmHg 137.8 (20.5) 140.0 (18.2) −3.6 (−7.9/0.7) 0.10 −2.7 (−8.0/2.5) 0.30
Diastolic BP, mmHg 80.2 (10.1) 79.3 (10.5) −1.7 (−4.0/0.6) 0.15 −1.0 (−3.9/1.8) 0.47
Total cholesterol, mmol/l 4.2 (0.8) 4.6 (1.1) −0.1 (−0.3/0.2) 0.55 −0.2 (−0.5/0.1) 0.25
HDL cholesterol, mmol/l 1.3 (0.3) 1.4 (0.4) 0.02 (−0.1/0.1) 0.68 −0.0001 (−0.1/0.1) 0.99
Cholesterol/HDL ratio 3.3 (0.9) 3.4 (1.1) 0.06 (−0.2/0.3) 0.61 −0.1 (−0.4/0.2) 0.58
LDL cholesterol, mmol/l 2.2 (0.8) 2.4 (1.0) 0.001 (−0.2/0.2) 0.99 −0.1 (−0.3/0.2) 0.61
HbA1c,% 1 7.1 (1.8) 7.1 (1.3) −0.3 (−0.9/0.4) 0.38 −0.5 (−1.2/0.2) 0.14
Maximal work rate,Watt 146.1 (43.5) 156.4 (49.4) 6.9 (0.9/13.0)** 0.03 n.a.  
Maximal ergometry, METS 6.4 (1.6) 6.7 (1.8) 0.3 (0.1/0.5)** 0.01 n.a.  
  1. aAdjusted for age, sex, baseline value of outcome measure and bif appropriate also adjusted for smoking; B-values reflect differences between groups over time from baseline. CI = confidence interval; BP = blood pressure; HDL = ‘high density lipoprotein’; LDL = ‘low density lipoprotein’; HbA1c = glycolysed haemoglobin; n.a. = not applicable.
  2. 1only among patients with diabetes mellitus type 2; **p < 0.05.